What happened
Researchers at the UCLA Health Jonsson Comprehensive Cancer Center developed a new platform combining 3D bioprinting, advanced imaging, and artificial intelligence to monitor cancer treatment response. Published in Nature Protocols, the approach uses patient-derived cancer cells to create organoids, continuously tracking their drug response via high-speed, label-free quantitative phase imaging. AI then analyses the resulting data, enabling evaluation of hundreds of potential therapies simultaneously and quantifying drug responses at single-organoid resolution across thousands of samples.
Why it matters
This platform significantly reduces the time associated with identifying effective cancer therapies, shifting from population-average drug efficacy to individual organoid responses. For pharmaceutical research teams, this mechanism accelerates drug discovery by providing high-throughput screening capabilities for patient-derived tumor models. Clinical oncologists gain a tool to predict which therapies will work for a particular patient, especially for rare or hard-to-treat cancers, by testing drugs on a patient's own tumor cells before treatment begins.
